Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171574
Status:
COMPLETED
Last Update Posted:
2017-02-24
First Post:
2005-09-12
Brief Title:
Antiproteinuric Effect of Valsartan and Lisinopril
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Antiproteinuric Effect of Valsartan Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease a Randomized Double Blind Parallel Group Controlled Trial With 5 Months Follow-up
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Title Antiproteinuric effect of valsartan lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease a randomized 331 double blind parallel group controlled trial 5 months follow-up
Objective To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients
Hypothesis Combo treatment reduces microalbuminuria proteinuria and the albumincreatinin ratio more than monotherapies
Design Multicentric randomized double blind parallel group active controlled
Dose regimen Valsartan 320 vs Lisinopril 40 vs Valsartanlisinopril 16020
Objective To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients
Hypothesis Combo treatment reduces microalbuminuria proteinuria and the albumincreatinin ratio more than monotherapies
Design Multicentric randomized double blind parallel group active controlled
Dose regimen Valsartan 320 vs Lisinopril 40 vs Valsartanlisinopril 16020
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None